Niklas Mattsson; Ulf Andréasson; Henrik Zetterberg; Kaj Blennow; for the Alzheimer’s Disease Neuroimaging Initiative · 2017 · JAMA Neurology
Paper
Importance: Existing cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer disease (AD) are invasive or expensive. Biomarkers based on standard blood test results would be useful in research, drug development, and clinical practice. Plasma neurofilament light (NFL) has recently been proposed as a blood-based biomarker for neurodegeneration in dementias. Objective: To test whether plasma NFL concentrations are increased in AD and associated with cognitive decline, other AD biomarkers, and imaging evidence of neurodegeneration. Design, Setting, and Participants: In this prospective case-control study, an ultrasensitive assay was used to measure plasma NFL concentration in 193 cognitively healthy controls, 197 patients with mild cognitive impairment (MCI), and 180 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative. The study dates were September 7, 2005, to February 13, 2012. The plasma NFL analysis was performed in September 2016. Main Outcomes and Measures: Associations were tested between plasma NFL and diagnosis, Aβ pathologic features, CSF biomarkers of neuronal injury, cognition, brain structure, and metabolism. Results: Among 193 cognitively healthy controls, 197 patients with mild cognitive impairment, and 180 patients with AD with dementia, plasma NFL correlated with CSF NFL (Spearman ρ = 0.59, P <.001). Plasma NFL was increased in patients with MCI (mean, 42.8 ng/L) and patients with AD dementia (mean, 51.0 ng/L) compared with controls (mean, 34.7 ng/L) (P <.001) and had high diagnostic accuracy for patients with AD with dementia vs controls (area under the receiver operating characteristic curve, 0.87, which is comparable to established CSF biomarkers). Plasma NFL was particularly high in patients with MCI and patients with AD dementia with Aβ pathologic features. High plasma NFL correlated with poor cognition and AD-related atrophy (at baseline and longitudinally) and with brain hypometabolism (longitudinally). Conclusions and Relevance: Plasma NFL is associated with AD diagnosis and with cognitive, biochemical, and imaging hallmarks of the disease. This finding implies a potential usefulness for plasma NFL as a noninvasive biomarker in AD.
Analysis
This study found that plasma neurofilament light (NFL) is elevated in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), correlating with cognitive decline, brain atrophy, and hypometabolism, suggesting its utility as a noninvasive biomarker for AD.
Discovery
Dietmar Rudolf Thal; Koen Poesen; Rik Vandenberghe; Steffi De Meyer
Nicholas J. Ashton; Wagner S. Brum; Guglielmo Di Molfetta; Andréa Lessa Benedet; Burak Arslan; Erin M. Jonaitis; Rebecca E. Langhough; Karly Alex Cody; Rachael E. Wilson; Cynthia M. Carlsson; Eugeen Vanmechelen; Laia Montoliu‐Gaya; Juan Lantero‐Rodriguez; Nesrine Rahmouni; Cécile Tissot; Jenna Stevenson; Stijn Servaes; Joseph Therriault; Tharick A. Pascoal; Alberto Lleó; Daniel Alcolea; Juan Fortea; Pedro Rosa‐Neto; Sterling C. Johnson; Andreas Jeromin; Kaj Blennow; Henrik Zetterberg
Charles Bernick; Guogen Shan; Aaron Ritter; Nicholas J. Ashton; Kaj Blennow; Juan Lantero‐Rodriguez; Anniina Snellman; Henrik Zetterberg
Fernando González‐Ortiz; Michael Turton; Przemysław R. Kac; Denis S. Smirnov; Enrico Premi; Roberta Ghidoni; Luisa Benussi; Valentina Cantoni; Claudia Saraceno; Jasmine Rivolta; Nicholas J. Ashton; Barbara Borroni; Douglas Galasko; Peter Harrison; Henrik Zetterberg; Kaj Blennow; Thomas K. Karikari
Oskar Hansson; Rebecca M. Edelmayer; Adam L. Boxer; María C. Carrillo; Michelle M. Mielke; Gil D. Rabinovici; Stephen Salloway; Reisa A. Sperling; Henrik Zetterberg; Charlotte E. Teunissen
Henrik Zetterberg; Kaj Blennow
Source record